Related Experiment Video
Updated: Aug 19, 2026
Polygraphic Recording Procedure for Measuring Sleep in Mice
Published on: January 25, 2016
Automatic scoring of polygraphic sleep recordings: midazolam in insomniacs
Abstract:
Midazolam in doses of 0.21-0.46 mg/kg was given to four insomniacs for 27 days, and to a fifth insomniac for an additional 124 days, to assess its short, intermediate, long-term and long-standing efficacy. Automatic analysis of the polygraphic sleep recordings was carried out employing real-time signal processing (based on linear prediction), and an off-line sequential fuzzy clustering. Total sleep length did not vary significantly during medication, whereas other efficacy parameters such as sleep onset latency, wake time after sleep onset and number of nightly awakenings decreased significantly throughout the period of active medication. In one patient, midazolam was still effective after 151 days of administration. The ultrashort action (probably 3-4 h) of midazolam could be demonstrated by the distribution of the efficacy parameters, dividing the night into 2-h periods, by the unchanged total sleep length during medication compared with baseline and by the lack of any subjective clinical symptoms of hangover. The quantitative analysis of the signals showed that, although a decrease in the total amount of slow-wave sleep during long-term medication and withdrawal was detected, the total relative power in the delta band increased during drug administration. This was interpreted as redistribution of the delta activity during active medication. A lengthening of REM sleep was found during active medication probably attributable to intranight rebound. This was not followed by any clinical symptom of clinical REM rebound.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Midazolam effectively reduces insomnia symptoms like prolonged sleep onset and frequent awakenings. Its ultrashort action and sustained efficacy suggest potential for long-term insomnia management.
Area of Science:
- Pharmacology
- Sleep Medicine
- Neuroscience
Background:
- Insomnia is a prevalent sleep disorder affecting millions worldwide.
- Current treatments for insomnia have limitations and potential side effects.
- Understanding the efficacy of medications like midazolam is crucial for effective insomnia management.
Purpose of the Study:
- To assess the short, intermediate, long-term, and long-standing efficacy of midazolam in treating insomnia.
- To investigate the effects of midazolam on various sleep parameters using objective polygraphic recordings.
- To evaluate the pharmacokinetic profile and potential side effects of midazolam during prolonged administration.
Main Methods:
- Administered midazolam (0.21-0.46 mg/kg) to five insomniacs for extended periods (27 to 151 days).
- Utilized automatic analysis of polygraphic sleep recordings with real-time signal processing and fuzzy clustering.
- Quantitatively analyzed sleep parameters including sleep onset latency, wake time, awakenings, total sleep length, slow-wave sleep, delta power, and REM sleep.
Main Results:
- Total sleep length remained consistent, but sleep onset latency, wake time after sleep onset, and nightly awakenings significantly decreased during medication.
- Midazolam demonstrated sustained efficacy in one patient for up to 151 days.
- Quantitative analysis revealed a redistribution of delta activity and an increase in REM sleep during midazolam administration, without clinical REM rebound.
Conclusions:
- Midazolam exhibits significant short-term and long-term efficacy in improving key insomnia parameters.
- The drug's ultrashort action (3-4 hours) is supported by sleep architecture analysis and lack of hangover symptoms.
- Midazolam shows promise as a potential therapeutic option for chronic insomnia management, warranting further investigation.
